{"Abstract": [0], "Hepatocellular": [1], "carcinoma": [2], "(HCC)": [3], "can": [4], "have": [5], "viral": [6], "or": [7, 161, 177, 200, 219, 253, 321], "non-viral": [8, 240, 271], "causes": [9], "1\u20135": [10], ".": [11, 43], "Non-alcoholic": [12], "steatohepatitis": [13], "(NASH)": [14], "is": [15, 38], "an": [16, 39, 108], "important": [17], "driver": [18], "of": [19, 31, 50, 66, 113, 121, 156, 204, 214, 306, 316], "HCC.": [20, 241], "Immunotherapy": [21], "has": [22], "been": [23], "approved": [24], "for": [25, 33, 304], "treating": [26], "HCC,": [27, 68, 272], "but": [28, 86], "biomarker-based": [29], "stratification": [30, 305], "patients": [32, 225, 238, 246, 262, 307], "optimal": [34], "response": [35], "to": [36, 90, 107, 171, 261, 280, 284, 295, 311], "therapy": [37, 232], "unmet": [40], "need": [41], "6,7": [42], "Here": [44], "we": [45], "report": [46], "the": [47, 111, 117], "progressive": [48], "accumulation": [49], "exhausted,": [51], "unconventionally": [52], "activated": [53, 77], "CD8": [54, 78, 129, 157, 166, 190], "+": [55, 57, 79, 81, 130, 132, 134, 137, 141, 158, 167, 191, 193], "PD1": [56, 80, 131, 192, 220], "T": [58, 82, 142, 159, 168, 194, 287], "cells": [59, 83, 160, 169, 195], "in": [60, 110, 116, 146, 188, 221, 237, 314], "NASH-affected": [61], "livers.": [62], "In": [63, 242], "preclinical": [64], "models": [65], "NASH-induced": [67], "therapeutic": [69], "immunotherapy": [70, 317], "targeted": [71], "at": [72], "programmed": [73], "death-1": [74], "(PD1)": [75], "expanded": [76], "within": [84], "tumours": [85], "did": [87, 233], "not": [88, 234], "lead": [89], "tumour": [91, 96, 122], "regression,": [92], "which": [93, 124], "indicates": [94], "that": [95, 165, 211, 230, 270, 293], "immune": [97, 179, 231, 297], "surveillance": [98], "was": [99, 152], "impaired.": [100], "When": [101], "given": [102], "prophylactically,": [103], "anti-PD1": [104, 150, 252], "treatment": [105, 151, 255], "led": [106], "increase": [109, 145], "incidence": [112], "NASH\u2013HCC": [114], "and": [115, 119, 139, 185, 273], "number": [118], "size": [120], "nodules,": [123], "correlated": [125], "with": [126, 198, 226, 239, 247, 263, 308], "increased": [127], "hepatic": [128, 189], "CXCR6": [133], ",": [135, 138], "TOX": [136], "TNF": [140, 162], "cells.": [143], "The": [144], "HCC": [147, 228, 249, 309], "triggered": [148], "by": [149, 154], "prevented": [153], "depletion": [155], "neutralization,": [163], "suggesting": [164], "help": [170], "induce": [172], "NASH\u2013HCC,": [173, 275], "rather": [174], "than": [175, 223], "invigorating": [176], "executing": [178], "surveillance.": [180, 298], "We": [181], "found": [182], "similar": [183], "phenotypic": [184], "functional": [186], "profiles": [187], "from": [196], "humans": [197], "NAFLD": [199], "NASH.": [201], "A": [202], "meta-analysis": [203], "three": [205], "randomized": [206], "phase": [207], "III": [208], "clinical": [209], "trials": [210], "tested": [212], "inhibitors": [213], "PDL1": [215], "(programmed": [216], "death-ligand": [217], "1)": [218], "more": [222], "1,600": [224], "advanced": [227], "revealed": [229], "improve": [235], "survival": [236, 259], "two": [243], "additional": [244], "cohorts,": [245], "NASH-driven": [248], "who": [250], "received": [251], "anti-PDL1": [254], "showed": [256], "reduced": [257], "overall": [258], "compared": [260], "other": [264], "aetiologies.": [265], "Collectively,": [266], "these": [267], "data": [268, 300], "show": [269], "particularly": [274], "might": [276], "be": [277], "less": [278], "responsive": [279], "immunotherapy,": [281], "probably": [282], "owing": [283], "NASH-related": [285], "aberrant": [286], "cell": [288], "activation": [289], "causing": [290], "tissue": [291], "damage": [292], "leads": [294], "impaired": [296], "Our": [299], "provide": [301], "a": [302, 319], "rationale": [303], "according": [310], "underlying": [312], "aetiology": [313], "studies": [315], "as": [318], "primary": [320], "adjuvant": [322], "treatment.": [323]}